Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to follow the study requirements
• People aged 18 or older
• People who have been diagnosed with colorectal cancer (a specific type called adenocarcinoma) that cannot be removed by surgery, confirmed by a laboratory test
• People who have already completed at least 12 weeks of a specific type of second-line chemotherapy combined with a drug called bevacizumab, and whose cancer responded to or stayed stable during that treatment
• People whose last dose of that second-line treatment was no more than 6 weeks before joining this trial
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose general physical fitness is rated as reasonably functional on a standard medical scale (confirm with trial site)
• People whose doctors estimate they have a life expectancy of at least 12 weeks
• People whose major organs (such as liver, kidneys, and blood) are functioning well enough, based on tests
• Women who could become pregnant must agree to use reliable contraception or avoid sexual intercourse from the time of joining until at least 90 days after the last dose, must have a negative pregnancy test, and must not be breastfeeding
• Male participants whose partner could become pregnant must agree to use reliable contraception or avoid sexual intercourse from signing up until at least 90 days after the last dose, and must agree not to donate sperm during that same period

Who may not be able to join:

• People who still have side effects from previous cancer treatment that have not fully resolved (except hair loss, skin darkening, or nerve-related side effects from chemotherapy)
• People with a known history of lung disease involving scarring of lung tissue, or ongoing non-infectious lung inflammation
• People with poorly controlled high blood pressure (above certain levels) combined with a history of a blood pressure crisis or blood pressure-related brain condition
• People who have a tendency to bleed or are considered at high risk of bleeding
• People with known inherited or acquired bleeding or clotting disorders (such as haemophilia), or who have recently used full-dose blood-thinning or clot-dissolving medications (low-dose aspirin or low-molecular-weight heparin for prevention is allowed)
• People who have had a stroke, mini-stroke, brain bleed, brain infarction, or blood clot in the lungs within the 6 months before starting the study
• People with severe wounds that have not healed, open ulcers, or untreated broken bones
• People who have had major surgery within 4 weeks before the study starts, or who are expected to need major surgery during the study
• People who cannot swallow tablets or have a condition that affects how the body absorbs food or medication through the digestive system
• People with a known condition that weakens the immune system, such as HIV infection
• People with active hepatitis B or hepatitis C, based on specific blood test results (confirm with trial site)
• People with known cancer that has spread to the brain or the lining of the brain
• People who have had an active infection or unexplained fever above 38.5°C within 2 weeks before starting the study (fever clearly caused by the tumour may still be eligible — confirm with trial site)
• People with an acute or ongoing bowel blockage, or a chronic inflammatory bowel condition
• People with poorly controlled heart-related conditions or symptoms
• People who have had another type of cancer within the past 5 years, except for certain skin cancers or early-stage cervical cancer
• Women who are pregnant or breastfeeding
• People whose tumour has a specific genetic marker called MSI-H
• People who have previously been treated with a drug called TAS-102
• People who have had an abdominal fistula, a hole in the gastrointestinal tract, or an abdominal abscess within 6 months before starting the study
• People who the trial doctors consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.